Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21691195 | 1.00 | TSHR (0.41) | TSHRHPGDCA4EPHX1LMNA | |
| SCHEMBL30306598 | 1.00 | TSHR (0.41) | TSHRHPGDCA4EPHX1LMNA | |
| SCHEMBL20048857 | 1.00 | TSHR (0.41) | TSHRHPGDCA4EPHX1LMNA | |
| SCHEMBL29827611 | 0.97 | TSHR (0.39) | TSHRHPGDCA4EPHX1LMNA | |
| SCHEMBL28529500 | 0.86 | PDCD1 (0.40) | TSHREPHX1LMNAPDE4BMAPT | |
| SCHEMBL11052511 | 0.78 | TSHR (0.33) | TSHRHPGDEPHX1LMNAEPHX2 | |
| SCHEMBL30017163 | 0.78 | TSHR (0.37) | TSHRHPGDCA4EPHX1LMNA | |
| SCHEMBL3088326 | 0.78 | EPHX1 (0.37) | TSHRHPGDEPHX1LMNAEPHX2 | |
| SCHEMBL12238362 | 0.77 | ALDH1A1 (0.46) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL7717102 | 0.77 | ALDH1A1 (0.46) | TSHRLMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046071-A1 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES | ESTETRA SRL (BE) | 2025-03-06 | — | — | WO | claimed |
| US-11053273-B2 | Process for the production of estetrol intermediates | ESTETRA S.P.R.L. (BE) | 2021-07-06 | — | — | US | claimed |
| EP-2714712-B1 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES | ESTETRA SPRL (BE) | 2016-08-24 | — | — | EP | claimed |
| CN-103619867-B | For generation of the method for oestetrol intermediate | ESTETRA S.A. (BE) | 2015-12-23 | — | — | CN | claimed |
| US-20140107091-A1 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES | ESTETRA S.A. (BE) | 2014-04-17 | — | — | US | claimed |
| CN-103619867-A | Process for the production of estetrol intermediates | ESTETRA S A | 2014-03-05 | — | — | CN | claimed |
| WO-2012164095-A1 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES | ESTETRA S.A. (BE) | 2012-12-06 | — | — | WO | claimed |
| US-7868023-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-11 | — | — | US | claimed |
| EP-1863785-B1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2009059765-A2 | PROCESS FOR THE PREPARATION OF DROSPIRENONE | CHORISIS S.R.L. (IT) | 2009-05-14 | — | — | WO | claimed |
| US-7531658-B2 | Reacting 17-carboxylic acid-3-oxo-4-azasteroid with carbonyl- or sulfinyl-diimidazole and amidating the product with an amime in the presence of a heterocyclic hydroxyl activator; avoids the use of expensive and moisture sensitive organomagnesium halide; preparing Finasteride and Dutasteride | APOTEX PHARMACHEM INC. (CA) | 2009-05-12 | — | — | US | claimed |
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | SUBASINGHE NALIN L | 2008-10-16 | — | — | US | claimed |
| WO-2008101308-A1 | PROCESS FOR THE PREPARATION OF 17-N-SUBSTITUTED-CARBAMOYL-4-AZA-ANDROST-1 -EN-3-ONES | APOTEX PHARMACHEM INC. (CA) | 2008-08-28 | — | — | WO | claimed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | claimed |
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | APOTEX PHARMACHEM INC. (CA) | 2007-07-26 | — | — | US | claimed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | claimed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | claimed |
| EP-1586579-A1 | Process for the preparation of delta(15-16)-17-ketosteroids and use thereof in the synthesis of pharmacologically active compounds | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| EP-0022495-B1 | 2-ALKOXYPHENYL-IMIDAZO(4,5-B)PYRIDINES, THEIR PREPARATION, THEIR USE IN THE PRODUCTION OF MEDICAMENTS AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1982-06-16 | — | — | EP | claimed |
| US-4327100-A | USEFUL AS HYPERTENSIVE AND CARDIOTONIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1982-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255108-A1 | NOVEL THIOPHENE SULFOXIMINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | C5, C1R, C1QBP | TSHR 136/4885HPGD 1638/4885CA4 859/4885 |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | C5, C1QBP, C1R | TSHR 193/4885HPGD 1458/4885CA4 979/4885 |
| US-20070173523-A1 | Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones | CYP17A1, CYP19A1, NR5A1 | TSHR 1206/4885HPGD 274/4885CA4 729/4885 |
| US-11053273-B2 | Process for the production of estetrol intermediates | SULT1A1, DHCR7, SULT1E1 | TSHR 1313/4885HPGD 2503/4885CA4 727/4885 |
| US-20140107091-A1 | PROCESS FOR THE PRODUCTION OF ESTETROL INTERMEDIATES | DHCR7, SULT1A1, SULT1E1 | TSHR 1406/4885HPGD 2622/4885CA4 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.